ReviewFrontiers in pharmacology2018
P2Y
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 63 citations in OpenAlex.
- Platelet-neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- LRRC8 complexes are ATP release channels that regulate platelet activation and arterial thrombosis.Blood · 2025Article
- P2 purinergic receptors regulate the progression of colorectal cancer.Purinergic signalling · 2025Review
- Role and recent progress of P2Y12 receptor in cancer development.Purinergic signalling · 2025Review
- ENTPD1 (CD39) and NT5E (CD73) expression in human medulloblastoma: an in silico analysis.Purinergic signalling · 2025Article
- Molecular Insights into the Relationship Between Platelet Activation and Endothelial Dysfunction: Molecular Approaches and Clinical Practice.Molecular biotechnology · 2024Review
- Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis.British journal of cancer · 2024Article
- Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer.Frontiers in oncology · 2024Review
- Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention.Frontiers in pharmacology · 2024Review
- The Signaling Pathway of the ADP Receptor P2YInternational journal of molecular sciences · 2023Review
- Estrogen depletion modulates aortic prothrombotic signaling in normotensive and spontaneously hypertensive female rats.Molecular and cellular endocrinology · 2023Article
- Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs.Pharmaceuticals (Basel, Switzerland) · 2022Review
- P2YPurinergic signalling · 2022Article
- Platelets involved tumor cell EMT during circulation: communications and interventions.Cell communication and signaling : CCS · 2022Review
- Intratumoral Platelets: Harmful or Incidental Bystanders of the Tumor Microenvironment?Cancers · 2022Review
- Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling.Purinergic signalling · 2022Review
- Review
- Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies.Frontiers in pharmacology · 2022Review
- A new era: tumor microenvironment in chemoresistance of pancreatic cancer.Journal of cancer science and clinical therapeutics · 2022Article
- P2YMolecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets, beyond their role in hemostasis and thrombosis, may sustain tumorigenesis and metastasis. These effects may occur via direct interaction of platelets with cancer and stromal cells and by the release of several platelet products. Platelets and tumor cells release several bioactive molecules among which a great amount of adenosine triphosphate (ATP) and adenosine diphosphate (ADP). ADP is also formed extracellularly from ATP breakdown by the ecto-nucleoside-triphosphate-diphosphohydrolases. Under ATP and ADP stimulation the purinergic P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.